Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trophos, a clinical stage pharma firm developing therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has started clinical development of new cardioprotective compound TRO40303 (3,5seco-4-nor-cholestan-5-one oxime-3-ol), a new mitochondria pore modulator.
Subscribe to our email newsletter
TRO40303 is indicated to reduce the cardiac reperfusion injury that contributes to the morbidity and mortality seen post myocardial infarction (MI).
TRO40303 study is expected to recruit healthy volunteers and will compare the safety and tolerability of a single dose of the drug to placebo.
Trophos CEO Damian Marron said that the initiation of the clinical development of their second mitochondrial pore modulator, TRO40303, represents a major advance for Trophos.
TRO40303 Phase 1 study objective is to assess the safety, tolerability and pharmacokinetics of single escalating doses of TRO40303 as an intravenous infusion at different rates compared with placebo in 64 healthy volunteers.
The mechanism of action of TRO40303 involves prevention of stress-induced mitochondrial permeability transition, a target implicated in cardiac reperfusion injury.